13 March 2026
13 March 2026
Lilly is warning the public that tirzepatide mixed with B12 is creating an impurity with “unknown effects” in humans.
The selective muscarinic agonist is now in mid-stage development for movement disorders like Parkinson’s disease and dystonia.
While the injectable retains convenience advantages in dosing frequency, the pill addresses needle aversion and may facilitate broader uptake in primary care settings.
WHO’s director of antimicrobial resistance, Dr Yvan Hutin, says science needs to catch up with drug-resistant bacteria.
PsiQuantum will work with the National Cancer Center Japan to develop fault-tolerant algorithms and quantum applications.
The collaboration targets disease areas where conventional small molecule drug discovery has faced challenges.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
